RussellZeligSzmulewitzMD

Genitourinary Oncology

Associate Professor of Medicine, University of Chicago Medicine

Overview of Dr. Szmulewitz

Dr. Russell Szmulewitz is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 14 years. Dr. Szmulewitz accepts several types of health insurance, listed below. He is one of 123 doctors at University of Chicago Medical Center who specialize in Oncology. He has more than 80 publications and over 500 citings.

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Book by Phone+1(877) 791-5016

Fax+1 773-702-3163
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

IL State Medical License 2006 - 2026
NY State Medical License 2005 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Pazopanib, Docetaxel, Prednisone Prostate Start of enrollment: 2011 Jun 01
Completed
Phase 1
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Start of enrollment: 2012 May 01
Completed
Phase 2
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer Start of enrollment: 2013 Dec 13
Completed
Phase 1, Phase 2
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Start of enrollment: 2018 Oct 23
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Prostate Cancer, Version 3.2024.
Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda Bitting, Brian Chapin, Heather H Cheng, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A Eastham,...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 1
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Z Szmulewitz> ;Clinical Cancer Research. 2024 Mar 27
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Park, J., Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McD...> ;Clinical Cancer Research. 2024 Mar 15
Bladder-Preserving Trimodality Therapy With Capecitabine.
Connor Lynch, Randy F Sweis, Parth Modi, Piyush K Agarwal, Russell Z Szmulewitz, Walter M Stadler, Peter H O'Donnell, Stanley L Liauw, Sean P Pitroda> ;Clinical Genitourinary Cancer. 2024 Apr 1
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga, F., Azad, A., Iguchi, T., Villers, A., Alcaraz, A., Alekseev, B., Rosbrook, B., Zohren, F., Ma, J., Haas, G., Stenzl, A., Szmulewitz, R., Holzbeierlein, J...> ;European Urology Oncology. 2023 Dec 9
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.
Lynda Bennett, Praveen Kumar Jaiswal, Ryan V Harkless, Tiha M Long, Ning Gao, Brianna Vandenburg, Phillip Selman, Ishrat Durdana, Donald Vander Griend, Remi Adelaiye-O...> ;Molecular Cancer Therapeutics. 2024 Apr 2
1 citations
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Jason P Meier, Hannah J Zhang, Richard Freifelder, Mohammed Bhuiyan, Phillip Selman, Megan Mendez, Pavithra H A Kankanamalage, Thomas Brossard, Antonino Pusateri, Hsiu...> ;Molecules. 2023 Aug 13
1 citations
A usability and participatory design study for GeRI, an open-source, remote cancer treatment toxicity and frailty monitoring platform for older adults.
Nabiel Mir, Gina Curry, Nita Karnik Lee, Russell Zelig Szmulewitz, Megan Huisingh-Scheetz> ;Journal of Geriatric Oncology. 2024 Jan 1
2 citations
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Andrew J Armstrong, Taro Iguchi, Arun A Azad, Arnauld Villers, Boris Alekseev, Daniel P Petrylak, Russell Z Szmulewitz, Antonio Alcaraz, Neal D Shore, Jeffrey Holzbeie...> ;European Urology. 2023 Aug 1
2 citations
SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
Anthony Williams, Lisa Gutgesell, Larischa de Wet, Phillip Selman, Arunangsu Dey, Mahati Avineni, Isha Kapoor, Megan Mendez, Ryan Brown, Sophia Lamperis, Chuck Blajszc...> ;Cancer Letters. 2023 Jul 1
3 citations
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J George, David M Nanus, Emmanuel S Antonarakis, Daniel C Danila, Russell Z Szmulew...> ;Clinical Cancer Research. 2023 May 15
1 citations
Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review.
Nabiel Mir, Olivia Burke, Samuel Yates, Tanujaa Rajasekaran, Johan Chan, Russell Szmulewitz, Ravindran Kanesvaran> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
5 citations
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Zachary Quinn, Benjamin Leiby, Guru Sonpavde, Atish D Choudhury, Christopher Sweeney, David Einstein, Russell Szmulewitz, Oliver Sartor, Karen Knudsen, Eddy Shih-Hsin ...> ;Clinical Cancer Research. 2023 Jan 4
Editorial Comment.
Ted A Skolarus, Russell Z Szmulewitz> ;The Journal of Urology. 2022 Nov 1
1 citations
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore, Fr...> ;The Prostate. 2022 Sep 1
83 citations
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Arun A Azad, Taro Iguchi, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D ...> ;Journal of Clinical Oncology. 2022 May 20
6 citations
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Ivan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J Small, Terence Friedlander, Lawrence Fong, Pamela L Paris, Charles ...> ;Clinical Cancer Research. 2022 Apr 14
12 citations
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Anthony V Serritella, Daniel Shevrin, Elisabeth I Heath, James L Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M Stadl...> ;Clinical Cancer Research. 2022 Apr 14
21 citations
SOX2 mediates metabolic reprogramming of prostate cancer cells.
Larischa de Wet, Anthony Williams, Marc Gillard, Steven Kregel, Sophia Lamperis, Lisa C Gutgesell, Jordan E Vellky, Ryan Brown, Kelly Conger, Gladell P Paner, Heng Wan...> ;Oncogene. 2022 Feb 1
2 citations
Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells.
Larischa de Wet, Anthony Williams, Marc Gillard, Steven Kregel, Sophia Lamperis, Lisa C Gutgesell, Jordan E Vellky, Ryan Brown, Kelly Conger, Gladell P Paner, Heng Wan...> ;Oncogene. 2022 Feb 1
3 citations
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patient...
Rahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, Celestia S Higano, Alan H Bryce, Angela Lopez-Gitlitz, Sharon A McCarthy, Branko Miladinovic, Kelly McQuarrie, S...> ;Prostate Cancer. 2022 Jan 1
4 citations
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial.
Brian L. Heiss, Daniel M. Geynisman, Elia Martinez, Alvin Wong, Wei Peng Yong, Russell Z. Szmulewitz, Walter M. Stadler> ;Supportive Care in Cancer. 2021 Nov 29
12 citations
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun Azad, Andrew J. Armstrong, Antonio Alcaraz, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Boris Alekseev, Taro Iguchi, Nea...> ;Prostate Cancer and Prostatic Diseases. 2021 Aug 21
32 citations
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Russell K. Pachynski, Chihiro Morishima, Russell Z. Szmulewitz, Lauren C. Harshman, Leonard Joseph Appleman, Paul Monk, Rhonda L. Bitting, Omer Kucuk, Frederick Millar...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
20 citations
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
Howard I. Scher, Andrew J. Armstrong, Joseph D. Schonhoft, Audrey Gill, Jimmy L. Zhao, Ethan Barnett, Emily Carbone, J. Lu, Emmanuel S. Antonarakis, Jun Luo, Scott T. ...> ;European Journal of Cancer. 2021 Apr 21
Join now to see all

Press Mentions

Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 2August 26th, 2022
Benefits of PSMA-PET for High-risk/Advanced Prostate Cancer: Part 1August 26th, 2022
Taking a Standard Prostate Cancer Drug with Food Boosts Impact, Lowers CostMarch 30th, 2018
Join now to see all

Hospital Affiliations

University of Chicago Medical CenterChicago, Illinois

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
Cofinity PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
HealthLink PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment